Inspan The Future Of Single Position Lateral And Posterior Decompression And Fusion
March 19, 2022
Inspan is the first interspinous interlaminar spinous process fixation device to be FDA cleared for spinal stenosis and fusion.
Harvard-Trained Orthopedic Spine Surgeon Dr. Erik Spayde sees a growing application for Inspan to be used in a single position lateral interbody cage with its ability to fixate the construct posteriorly.
“I’ve always been a big believer in interspinous fixation. The ease with which the Inspan instrumentation works makes it preferred over pedicle screws in some indications such as to back up an Anterior lumbar interbody fusion or a Lateral lumbar interbody fusion”
- Dr. William Costigan, Board-Certified Orthopedic Spine Surgeon.
Dr. Joseph Aferzon & Dr. Jeffrey Bash together have performed over 700 Inspan cases supporting their anterior interbody fusion cases.
“This is much easier than placing pedicle screws and it allows for the surgeon to achieve posterior decompression and fusion for cases such as spondylolisthesis in which the lateral interbody cage may not be enough indirect decompression “
- Professor Kingsley R Chin MD, Harvard-Trained Board-Certified Orthopedic Spine Surgeon
Dr Kingsley R Chin’s case with unilateral facet screw adding stability to a lateral interbody cage
InSpan LLC is privately owned by the KICVentures Group and is focused on advancing the platform of patented interspinous interlaminar fixation technology. The InSpan device has a proven ten-year track record with thousands implanted since FDA clearance in 2010. There are no documented device-related failures or spinous process fractures that have plagued other competitive ISP devices.
https://MyInspan.com/
About KICVentures Group
Our founders have been investing in spine surgery 2000 makes us the most experienced healthcare investment holding company with the largest portfolio of medical device technologies focused on solutions for less invasive outpatient spine surgery. Our investment strategy is to acquire or invent disruptive technologies using our own capital or partner with private individual investors. This allows us the freedom to make quick and nimble decisions such as when we acquired AxioMed Viscoelastic Disc Technologies while other companies invested in spinal fusion.
http://www.KICVenturesGroup.com
Authors
​
Dr. Kingsley R. Chin MBA is a board-certified Professor of Orthopedic Spine Surgery and honors graduate of Harvard Medical School and the Harvard Combined Orthopedic Residency Program. He did his spine fellowship with Dr. Henry H Bohlman. He was Chief of Spine Surgery at the University of Pennsylvania.
​
​
Dr. Jason A. Seale MBA is a medical doctor and entrepreneur. He is the clinical director at the LES Clinic.